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The COVID-19 Vaccine Development Landscape
Tung Thanh Le et. al
COVID-19
● January 11, 2020
○ Publication of the genetic sequence of SARS-CoV-2
■ Led to the rapid development of vaccine for the virus
● About two months later…
○ March 16, 2020
■ The first COVID-19 vaccine began human clinical trials 
The Coalition for Epidemic Preparedness Innovations 
(CEPI) 
● Headquarters in Oslo, Norway
● A global coalition consisting of public, private, and philanthropic 
organizations





○ 115 Vaccine Candidates
■ 78 are confirmed and active
● 73 of which are currently in preclinical or exploratory stages
■ 37 unconfirmed  
■ Many vaccine developers plan for human testing trials in 2020
● Current Vaccines in Clinical Development 
○ Moderna: mRNA-1273
■ Began clinical testing 2 months after sequence identification
○ CanSino Biologicals: Ad5-nCoV
○ Inovio: INO-4800
○ Shenzhen Geno-Immune Medical Institute: LV-SMENP-DC and pathogen-specific aAPC 

Diversity in Vaccine Development Platforms
● Technology platforms include…
○ Nucleic Acid (DNA/RNA)
○  Virus-Like Particle
○ Peptide
○ Viral Vector (replicating and non-replicating)
○ Recombinant Protein 
○ Live attenuated virus and inactivated virus approaches
● It is possible that some vaccines may be most effective 
with specific populations such as elderly, pregnant 
women, and children 
Analysis of Current Vaccine Platforms
● Vaccines focused on DNA or mRNA 
○ offers promising versatility of antigen manipulation & speed
● Vaccines based on Viral Vectors
○ long-term stability, high level of protein expression, and 
induces strong immune responses
● Vaccines based on Recombinant Proteins
○ Previously licensed vaccines for other diseases
○ Pro: ability for large scale production due to the existing 
vaccines
Adjuvants
Definition: substances that may be added to a vaccine in order to produce a 
strong immune response to the vaccine
● Pros: potential for lower viable doses & enhance immunogenicity 
● GlaxoSmithKline, Seqirus, Dynavax 
Specifics in SARS-CoV-2 Vaccine Development
● Information about the specific antigens being used in vaccine 
development is limited
○ Available information describes the induction of neutralizing antibodies against the viral 
spike (S) protein, preventing uptake via the human ACE2 receptor
● Current research has not yet determined how the S protein relates to its 
various other forms and COVID-19
72% - private/industry developers   
28% - academic, public sector, and other non-profit organizations
46% - developers in North America       18% - China
18% - Asia (excluding China)                   18% - Europe
Conclusion 
● Possible vaccines may be available by early 2021
○ Emergency use ONLY
● Average vaccine development usually takes around 10 years
○ Ebola Virus : 5 year development of a vaccine
● Development of COVID-19 Specific Animal Models
○ ACE2-transgenic mice 
○ Hamsters
○  ferrets
○  non-human primates
Discussion Questions
● Is it more likely for developers in another country, such as China, to 
finalize a vaccine before the US? 
● How do you think the current lack of a vaccine will affect the rate of the 
spread of the virus?
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